INTI Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 21:44):

Stats
Dagens volum	1 250.00
Gjennomsnittsvolum	9 237.00
Markedsverdi	14.79M
EPS	$0 ( 2024-03-29 )
Neste inntjeningsdato	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.30
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-11	Osman Ronald E	Buy	25 000	Common Stock
2023-05-05	Ronald E Osman Irrevocable Trust Iii	Sell	0	Common Stock
2023-05-05	Tpb 2012 Llc	Buy	0	Common Stock
2023-05-05	Tpb 2012 Llc	Sell	0	Common Stock
2023-05-05	Mcnulty James A	Buy	20 101 057	Common Stock

INSIDER POWER
-57.75
Last 91 transactions
Buy: 128 793 757 \| Sell: 121 688 284

Inhibitor Therapeutics, Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Inhibitor Therapeutics, Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.0176

FY	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.0176

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$0.0325

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.000803

Financial Reports:

No articles found.

Inhibitor Therapeutics,

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.